Sudhakar Girotra
Interventional Cardiology · Farmington, NMNPI 1710184163
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,331 of the $7,317 with a category attached, or 72.9%. 6 manufacturers reported payments, led by Abbott at 27.0% of the total.
Across 65 payments — averaging $112.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Philips North America LLC$2K
- Edwards Lifesciences$2K
- Medtronic$1K
- Boston Scientific$373
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$59
What the payments were for
- Travel & lodging$5,33173%
- Food & beverage$1,98627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,978 |
| Philips North America LLC | 10 | $1,787 |
| Edwards Lifesciences | 9 | $1,687 |
| Medtronic(2 entities) | 18 | $1,433 |
| Boston Scientific | 15 | $373 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracardiac Undivided$1,694
- TRICLIP$1,609
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,413
- CoreValve Evolut$1,072
- ROTABLATOR$121
How this compares
$7,317 in reported general payments places this provider in the 55th percentile of 25 interventional cardiology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $267,987 |
| EliquisApixaban | 107 | $96,136 |
| BrilintaTicagrelor | 35 | $25,016 |
| Praluent PenAlirocumab | 42 | $24,335 |
| XareltoRivaroxaban | 23 | $16,930 |
| EntrestoSacubitril/Valsartan | 14 | $16,177 |
| VascepaIcosapent Ethyl | 12 | $8,886 |
| Rosuvastatin Calcium | 85 | $1,189 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 92 | $1,153 |
| Atorvastatin Calcium | 147 | $1,048 |
| Ezetimibe | 63 | $947 |
| Ranolazine ErRanolazine | 20 | $850 |
| Metoprolol Succinate | 63 | $776 |
| Carvedilol | 31 | $631 |
| ClopidogrelClopidogrel Bisulfate | 29 | $541 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Farmington
- Richard BlankenbakerFarmington$13K
- Stephen BernardFarmington$3K
- Darren RamoutarFarmington$2K
- Stephen MackerrowFarmington$656
- Mark BieniarzAlbuquerque$207K
- Raymond YauAlbuquerque$171K
- Robert FedericiAlbuquerque$77K
- Abdul KhanLas Cruces$23K
- Sharif HalimAlbuquerque$22K
- Geoffrey KunzAlbuquerque$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.